Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 8.01 (Other Events). Teva patent litigation over Jelmyto resolved through settlement and license agreement.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Teva patent litigation over Jelmyto resolved through settlement and license agreement
- Teva generic Jelmyto entry permitted beginning September 15, 2030, subject to FDA approval
- Agreement extends branded Jelmyto exclusivity until 2030, supporting near-term revenue protection
- Ongoing Delaware patent litigation will terminate, reducing legal uncertainty and costs
- Settlement remains subject to FTC and DOJ review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.